We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
24 Jan 2022 - 27 Jan 2022

Global Point-of-Care Coagulation Testing Market to Be Driven by Growing Geriatric Population

By LabMedica International staff writers
Posted on 08 Dec 2021
Print article

The global point-of-care (POC) coagulation testing market is set to achieve significant growth on the back of the growing geriatric population and increasing technological innovations in POC testing, although the lack of trained professionals will hamper market growth.

These are the latest findings of Technavio (New York, NY, USA), a global technology research and advisory company.

The growing geriatric population is expected to fuel the growth of the POC coagulation testing market. Aging increases the susceptibility to infections as the immune system deteriorates with age. Older adults require diagnostic testing on a regular basis due to their low immunity and slow metabolism. These factors have increased the demand for POC blood coagulation analyzers as coagulation measurements can assist in diagnosing diseases. Physicians use the results of these blood tests to choose the most suitable line of treatment. Hence, an increasing older adult population indicates a growing demand for POC coagulation testing, thus contributing to the market growth.

However, the inability to hire trained professionals will limit the use of POC coagulation analyzers, which could hinder market growth. There is a shortage of these specialists in diagnostic centers and hospitals globally. Generally, most rural hospitals face issues such as the lack of patient volume required to justify having specialists. Most times, appointing in-house specialists is cost-prohibitive, especially for small medical facilities. Therefore, end-users such as hospitals and diagnostic centers will need to invest significantly in providing training to their employees for laboratory testing and maintaining POC coagulation analyzers.

The hospitals and clinics segment hold the largest share of the global POC coagulation testing market and will be the key driver of the market growth, owing to the significant use of POC coagulation testing analyzers during perioperative procedures for the timely determination of coagulopathies (bleeding disorders) and hemostatic functions in patients. This helps in preventing unanticipated bleeding and perioperative mortality. Hospitals and clinics use globally accepted POC coagulation testing procedures such as aPTT and INR, which significantly reduce the turnaround time and allow medical practitioners to make fast decisions during critical situations.

Geographically, a majority of the growth of the global POC coagulation testing market will originate from North America due to an increase in laboratory automation, a shift toward rapid diagnostic tests, and increased number of Food & Drug Administration (FDA) approvals for new diagnostic procedures such as liquid biopsy and microbial tests. The US is a key market for POC coagulation testing in North America. However, the North American market for POC coagulation testing is expected to grow at a slower pace than the market in Asia and Europe.

Related Links:

Gold Supplier
TBI Blood Test
i-STAT TBI Plasma Test
Automated Nucleic Acid Extraction System
5-Part Diff Hematology Analyzer
Live Cell Analysis System
BioTek BioSpa

Print article
IIR Middle East


Molecular Diagnostics

view channel

Point-of-Care Lateral Flow Test Detects Bladder Cancer Using Urine Sample within Minutes

A breakthrough diagnostics platform uses a multiplexed lateral flow assay that detects 10 bladder cancer biomarkers from a urine sample in either laboratory or point-of-care settings. SCIENION (Berlin,... Read more


view channel
Image: Bone marrow aspirate from a patient with Acute Myeloid Leukemia: Blasts are the predominant population and have a high nuclear to cytoplasmic ratio and generally lack granules. (Photo courtesy of Professor Peter G. Maslak, MD)

Cord Blood and Matched Related Donor Transplantation Compared in Acute Myeloid Leukemia

The prognosis of primary refractory and relapsed acute myeloid leukemia is poor, with a five-year overall survival of less than 10%. Allogeneic hematopoietic stem cell transplantation (HSCT) is the only... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.